Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.50 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NMT2 | O60551 | 1/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.37 |
| ▸ | JMJD6 | Q6NYC1 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL409282 | 0.81 | LMNA (0.50) | SMN1; SMN2NPC1RAB9AKMT2AHPGD | |
| SCHEMBL2114045 | 0.80 | SMN1; SMN2 (0.54) | CDC7DBF4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21523592 | 0.78 | CDC7 (0.53) | CDC7DBF4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29751844 | 0.78 | PIM2 (0.49) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL12571304 | 0.78 | PIM2 (0.49) | SMN1; SMN2NPC1RAB9AKMT2AALDH1A1 | |
| SCHEMBL11602666 | 0.76 | CYP1A2 (0.49) | SMN1; SMN2HPGDALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL11509779 | 0.73 | PPARG (0.48) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 | |
| SCHEMBL892695 | 0.73 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9AKMT2AHPGD | |
| SCHEMBL1800827 | 0.73 | HCAR2 (0.58) | NPC1RAB9AKMT2AALDH1A1MAPT | |
| SCHEMBL7669777 | 0.72 | CYP1A2 (0.44) | SMN1; SMN2NPC1RAB9AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041727-B1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-119823112-A | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115135645-B | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20220389001-A1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220389001-A1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS, INC. | 2022-12-08 | — | — | US | disclosed |
| CN-115135645-A | ATF6 modulators and uses thereof | 普拉西斯生物技术有限责任公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-4041727-A1 | ATF6 MODULATORS AND USES THEREOF | Praxis Biotech LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021069701-A1 | ATF6 MODULATORS AND USES THEREOF | BLACK BELT TX LTD (GB) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021069701-A1 | ATF6 MODULATORS AND USES THEREOF | BLACK BELT TX LTD (GB) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389001-A1 | ATF6 MODULATORS AND USES THEREOF | ATF4, XBP1, ATF1 | CDC7 2468/4885DBF4 1323/4885SMN1; SMN2 1282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.